# Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?

Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible... After the introduction of the prostate specific antigen (PSA) test in the 1980s, a sharp increase in the incidence rate of prostate cancer was seen in the United States. The age-specific incidence patterns exhibited remarkable shifts to younger ages, and declining rates were observed at old ages. Similar trends were seen in Norway. We investigate whether these features could, in combination with PSA testing, be explained by a varying degree of susceptibility to prostate cancer in the populations. We analyzed incidence data from the United States’ Surveillance, Epidemiology, and End Results program for 1973–2010, comprising 511,027 prostate cancers in men ≥40 years old, and Norwegian national incidence data for 1953–2011, comprising 113,837 prostate cancers in men ≥50 years old. We developed a frailty model where only a proportion of the population could develop prostate cancer, and where the increased risk of diagnosis due to the massive use of PSA testing was modelled by encompassing this heterogeneity in risk. The frailty model fits the observed data well, and captures the changing age-specific incidence patterns across birth cohorts. The susceptible proportion of men is $$39.9\,\%\,\left( {95\,\%\,{\text{CI}}\, 38.2, 41.6\,\% } \right)$$ 39.9 % 95 % CI 38.2 , 41.6 % in the United States and $$30.4\,\%\, \left( {95\,\%\, {\text{CI}} \,28.9, 32.0\,\% } \right)$$ 30.4 % 95 % CI 28.9 , 32.0 % in Norway. Cumulative incidence rates at old age are unchanged across birth cohort exposed to PSA testing at younger and younger ages. The peaking cohort-specific age-incidence curves of prostate cancer may be explained by the underlying heterogeneity in prostate cancer risk. The introduction of the PSA test has led to a larger number of diagnosed men. However, no more cases are being diagnosed in total in birth cohorts exposed to the PSA era at younger and younger ages, even though they are diagnosed at younger ages. Together with the earlier peak in the age-incidence curves for younger cohorts, and the strong familial association of the cancer, this constitutes convincing evidence that the PSA test has led to a higher proportion, and an earlier timing, of diagnoses in a limited pool of susceptible individuals. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Epidemiology Springer Journals

# Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?

10 pages

/lp/springer_journal/prostate-specific-antigen-testing-for-prostate-cancer-depleting-a-ZSZI29klci
Publisher
Springer Netherlands
Subject
Medicine & Public Health; Epidemiology; Public Health; Infectious Diseases; Cardiology; Oncology
ISSN
0393-2990
eISSN
1573-7284
D.O.I.
10.1007/s10654-016-0185-z
Publisher site
See Article on Publisher Site

### Abstract

After the introduction of the prostate specific antigen (PSA) test in the 1980s, a sharp increase in the incidence rate of prostate cancer was seen in the United States. The age-specific incidence patterns exhibited remarkable shifts to younger ages, and declining rates were observed at old ages. Similar trends were seen in Norway. We investigate whether these features could, in combination with PSA testing, be explained by a varying degree of susceptibility to prostate cancer in the populations. We analyzed incidence data from the United States’ Surveillance, Epidemiology, and End Results program for 1973–2010, comprising 511,027 prostate cancers in men ≥40 years old, and Norwegian national incidence data for 1953–2011, comprising 113,837 prostate cancers in men ≥50 years old. We developed a frailty model where only a proportion of the population could develop prostate cancer, and where the increased risk of diagnosis due to the massive use of PSA testing was modelled by encompassing this heterogeneity in risk. The frailty model fits the observed data well, and captures the changing age-specific incidence patterns across birth cohorts. The susceptible proportion of men is $$39.9\,\%\,\left( {95\,\%\,{\text{CI}}\, 38.2, 41.6\,\% } \right)$$ 39.9 % 95 % CI 38.2 , 41.6 % in the United States and $$30.4\,\%\, \left( {95\,\%\, {\text{CI}} \,28.9, 32.0\,\% } \right)$$ 30.4 % 95 % CI 28.9 , 32.0 % in Norway. Cumulative incidence rates at old age are unchanged across birth cohort exposed to PSA testing at younger and younger ages. The peaking cohort-specific age-incidence curves of prostate cancer may be explained by the underlying heterogeneity in prostate cancer risk. The introduction of the PSA test has led to a larger number of diagnosed men. However, no more cases are being diagnosed in total in birth cohorts exposed to the PSA era at younger and younger ages, even though they are diagnosed at younger ages. Together with the earlier peak in the age-incidence curves for younger cohorts, and the strong familial association of the cancer, this constitutes convincing evidence that the PSA test has led to a higher proportion, and an earlier timing, of diagnoses in a limited pool of susceptible individuals.

### Journal

European Journal of EpidemiologySpringer Journals

Published: Jul 18, 2016

## You’re reading a free preview. Subscribe to read the entire article.

### DeepDyve is your personal research library

It’s your single place to instantly
that matters to you.

over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month ### Explore the DeepDyve Library ### Search Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly ### Organize Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place. ### Access Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals. ### Your journals are on DeepDyve Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more. All the latest content is available, no embargo periods. DeepDyve ### Freelancer DeepDyve ### Pro Price FREE$49/month
\$360/year

Save searches from
PubMed

Create lists to

Export lists, citations